Italia markets closed

Biocartis Group NV (0R72.L)

LSE - LSE Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
1,7340+0,0143 (+0,83%)
Alla chiusura: 04:40PM GMT
Schermo intero
Chiusura precedente1,7197
Aperto1,7197
DenaroN/D x N/D
LetteraN/D x N/D
Min-Max giorno1,7200 - 1,7200
Intervallo di 52 settimane1,7200 - 1,7200
VolumeN/D
Media VolumeN/D
CapitalizzazioneN/D
Beta (5 anni mensile)1,52
Rapporto PE (ttm)N/D
EPS (ttm)N/D
Prossima data utiliN/D
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Press release Biocartis Group NV: Disclosure of transparency notification

    PRESS RELEASE - REGULATED INFORMATION 3 March 2023, 17:40 CET Disclosure of transparency notification Mechelen, Belgium, 3 March 2023 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces today, in accordance with Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers of which shares are admitted to trading on a regulated market and laying down miscellaneous prov

  • GlobeNewswire

    Press release Biocartis Group NV: Biocartis announces the US FDA 510(k) clearance for the Idylla™ MSI Test

    PRESS RELEASE 2 March 2023, 7:00 CET BIOCARTIS ANNOUNCES THE US FDA 510(k) CLEARANCE FOR THE IDYLLA™ MSI TEST Mechelen, Belgium, 2 March 2023 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces the U.S. Food and Drug Administration (FDA) 510(k) clearance1 for its fully automated Idylla™ MSI Test. This 510(k) clearance reinforces Biocartis’ commitment to enable clinical molecular diagnostics in the U.S. Now,

  • GlobeNewswire

    Press release Biocartis Group NV: Disclosure of Outstanding Voting Securities

    PRESS RELEASE - REGULATED INFORMATION 28 February 2023, 17:50 CET Disclosure of Outstanding Voting Securities Mechelen, Belgium, 28 February 2023 – Biocartis Group NV (the "Company" or "Biocartis"), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that in the course of February 2023 4.50% convertible bonds due 2026 in a principal amount of EUR 1,800 were converted into shares of the Company against the issuance of in total 1,613 shares of the Company. On 24